• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Harrow, Inc.

    Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Relaunches TRIESENCE®
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Announces Nashville Expansion
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow to Present at Three Investor Conferences in September in New York
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Announces Second Quarter 2024 Financial Results
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow to Attend 2024 ASRS Annual Meeting
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Provides TRIESENCE® Relaunch Update
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow to Present at Two Investor Conferences in May
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Announces First Quarter 2024 Financial Results
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Announces New Appointments to its Board of Directors
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Partners with Leading Healthcare Market Access Technology Platforms
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Completes Transfer of the TRIESENCE® New Drug Application
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow to Present at Two Investor Conferences in November
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Announces Third Quarter 2023 Financial Results
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.
    From Harrow, Inc.
    Via Business Wire
    Tickers HROW
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.